Vicapsys Life Sciences, Inc. (VICP)

About Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

Headquarters: Suwanee, GA · Employees: 2 · Website: https://vicapsys.com

Supply-chain relationships for VICP

• Safran SA (SAF.PA) — supplier

Frequently asked questions about Vicapsys Life Sciences, Inc. (VICP)

What is Vicapsys Life Sciences, Inc. (VICP)?

Vicapsys Life Sciences, Inc. (VICP) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on OTC. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.

Who are Vicapsys Life Sciences, Inc.'s key suppliers and customers?

Macroplane tracks Vicapsys Life Sciences, Inc.'s (VICP) supply chain. Key suppliers include Safran SA (SAF.PA).